6.48
전일 마감가:
$6.521
열려 있는:
$6.88
하루 거래량:
8,104
Relative Volume:
0.36
시가총액:
$23.65M
수익:
$11.68M
순이익/손실:
$-8.85M
주가수익비율:
-2.6888
EPS:
-2.41
순현금흐름:
$-14.61M
1주 성능:
+4.52%
1개월 성능:
+17.50%
6개월 성능:
-1.22%
1년 성능:
+237.50%
Pulmatrix Inc Stock (PULM) Company Profile
명칭
Pulmatrix Inc
전화
(888) 355-4440
주소
945 CONCORD STREET, FRAMINGHAM, MA
PULM을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
PULM
Pulmatrix Inc
|
6.48 | 22.64M | 11.68M | -8.85M | -14.61M | -2.41 |
![]()
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Pulmatrix Inc Stock (PULM) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2018-02-09 | 개시 | H.C. Wainwright | Buy |
Pulmatrix Inc 주식(PULM)의 최신 뉴스
Pulmatrix set for merger with Cullgen, seeks asset divestment By Investing.com - Investing.com South Africa
Enliven stops work on solid tumor drug; Pulmatrix to divest assets - Endpoints News
Pulmatrix Announces Divestment Plan for Assets - citybiz
Pulmatrix Announces First Quarter 2025 Financial Results and Div - GuruFocus
Pulmatrix, Inc. SEC 10-Q Report - TradingView
Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets | PULM Stock News - GuruFocus
Pulmatrix set for merger with Cullgen, seeks asset divestment - Investing.com
Pulmatrix to Divest Migraine Drug PUR3100 as Cullgen Merger Approaches: Q1 Earnings Detail Strategic Shift - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDUS, COOP, ICAD, PULM on Behalf of Shareholders - The Malaysian Reserve
PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc.PULM - marketscreener.com
(PULM) Proactive Strategies - news.stocktradersdaily.com
Geode Capital Management LLC Boosts Holdings in Pulmatrix, Inc. (NASDAQ:PULM) - Defense World
Pulmatrix, Inc. (NASDAQ:PULM) Holdings Cut by Renaissance Technologies LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
(PULM) Investment Analysis - news.stocktradersdaily.com
Pulmatrix appoints CBIZ as new auditor after Marcum resignation By Investing.com - Investing.com India
Pulmatrix appoints CBIZ as new auditor after Marcum resignation - Investing.com
Pulmatrix Will Discuss Progress At The Aegis Growth Conference On September 21, 2016 - BioSpace
Aspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide - The Globe and Mail
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - ACCESS Newswire
Pulmatrix : Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline - MarketScreener
Learn to Evaluate (PULM) using the Charts - news.stocktradersdaily.com
Pulmatrix Reports 2024 Financials and Merger Plans - TipRanks
Pulmatrix Inc. (PULM) reports earnings - Quartz
Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets - Nasdaq
Pulmatrix (NASDAQ:PULM) Stock Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World
Genfit’s up to €185M royalty deal; J&J’s Tremfya gets a Crohn’s approval - Endpoints News
(PULM) Trading Report - Stock Traders Daily
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, PULM, CCNE, TURN on Behalf of Shareholders - The Malaysian Reserve
2025-02-25 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, PULM, CCNE, TURN on Behalf of Shareholders | NDAQ:CCNE | Press Release - Stockhouse
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pulmatrix, Inc. (PULM) - TradingView
PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders - Business Wire
PULM stock soars to 52-week high, touches $8.5 amid robust gains - Investing.com India
PULM stock soars to 52-week high, touches $8.5 amid robust gains By Investing.com - Investing.com South Africa
Pulmatrix revises bylaws, changes voting standards - MSN
Pulmatrix revises bylaws, changes voting standards By Investing.com - Investing.com Nigeria
Pulmatrix's Unique Inhaled Drug Candidate Has "Blockbuster" Potential, Says CFO Bill Duke - ACCESS Newswire
Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain - The Manila Times
SEC Form 425 filed by Pulmatrix Inc. - Quantisnow
Cullgen Begins Phase 1 Dosing of its Potential - GlobeNewswire
Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail
Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com - Defense World
Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com - Defense World
Pulmatrix, Inc. Holds 2024 Annual Meeting of Stockholders – Final Voting Results Released - Defense World
Pulmatrix secures director positions and ratifies accounting firm - Investing.com India
Pulmatrix secures director positions and ratifies accounting firm By Investing.com - Investing.com Australia
StockNews.com Begins Coverage on Pulmatrix (NASDAQ:PULM) - Defense World
Pulmatrix Inc (PULM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):